AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...

Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.

Pharma giant AstraZeneca has reported positive results from a Phase III trial of its treatment for non-muscle-invasive ...

"The positive results for Imfinzi in the Potomac trial represent a significant advance that will potentially allow more patients with early-stage bladder cancer to benefit from this important ...

— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) ...